Skip Nav Destination
Melphalan 200 mg/m2 versus melphalan 100 mg/m2 in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study
Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV
Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study
Deletion of the p110β isoform of phosphoinositide 3-kinase in platelets reveals its central role in Akt activation and thrombus formation in vitro and in vivo
Issue Archive
March 11 2010
Table of Contents
INSIDE BLOOD
REVIEW ARTICLES
CLINICAL TRIALS AND OBSERVATIONS
Melphalan 200 mg/m2 versus melphalan 100 mg/m2 in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study
Clinical Trials & Observations
Antonio Palumbo,Sara Bringhen,Benedetto Bruno,Antonietta Pia Falcone,Anna Marina Liberati,Mariella Grasso,Roberto Ria,Francesco Pisani,Clotilde Cangialosi,Tommaso Caravita,Anna Levi,Giovanna Meloni,Andrea Nozza,Patrizia Pregno,Attilio Gabbas,Vincenzo Callea,Manuela Rizzo,Luciana Annino,Valerio De Stefano,Pellegrino Musto,Ileana Baldi,Federica Cavallo,Maria Teresa Petrucci,Massimo Massaia,Mario Boccadoro
Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV
Clinical Trials & Observations
Susanne Saussele,Michael Lauseker,Alois Gratwohl,Dietrich W. Beelen,Donald Bunjes,Rainer Schwerdtfeger,Hans-Jochem Kolb,Anthony D. Ho,Christiane Falge,Ernst Holler,Günter Schlimok,Axel R. Zander,Renate Arnold,Lothar Kanz,Robert Dengler,Claudia Haferlach,Brigitte Schlegelberger,Markus Pfirrmann,Martin C. Müller,Susanne Schnittger,Armin Leitner,Nadine Pletsch,Andreas Hochhaus,Joerg Hasford,Rüdiger Hehlmann,for the German CML Study Group
Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study
Clinical Trials & Observations
Ali T. Taher,Khaled M. Musallam,Mehran Karimi,Amal El-Beshlawy,Khawla Belhoul,Shahina Daar,Mohamed-SalahEldin Saned,Abdul-Hamid El-Chafic,Maria R. Fasulo,Maria D. Cappellini
HEMATOPOIESIS AND STEM CELLS
IMMUNOBIOLOGY
Skin-draining lymph nodes contain dermis-derived CD103− dendritic cells that constitutively produce retinoic acid and induce Foxp3+ regulatory T cells
Martin Guilliams,Karine Crozat,Sandrine Henri,Samira Tamoutounour,Pierre Grenot,Elisabeth Devilard,Béatrice de Bovis,Lena Alexopoulou,Marc Dalod,Bernard Malissen
MYELOID NEOPLASIA
Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia
Hideki Muramatsu,Hideki Makishima,Anna M. Jankowska,Heather Cazzolli,Christine O'Keefe,Nao Yoshida,Yinyan Xu,Nobuhiro Nishio,Asahito Hama,Hiroshi Yagasaki,Yoshiyuki Takahashi,Koji Kato,Atsushi Manabe,Seiji Kojima,Jaroslaw P. Maciejewski
Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34− fraction
David C. Taussig,Jacques Vargaftig,Farideh Miraki-Moud,Emmanuel Griessinger,Kirsty Sharrock,Tina Luke,Debra Lillington,Heather Oakervee,Jamie Cavenagh,Samir G. Agrawal,T. Andrew Lister,John G. Gribben,Dominique Bonnet
PLATELETS AND THROMBOPOIESIS
Deletion of the p110β isoform of phosphoinositide 3-kinase in platelets reveals its central role in Akt activation and thrombus formation in vitro and in vivo
Brief Report
Valérie Martin,Julie Guillermet-Guibert,Gaétan Chicanne,Cendrine Cabou,Martine Jandrot-Perrus,Monique Plantavid,Bart Vanhaesebroeck,Bernard Payrastre,Marie-Pierre Gratacap
RED CELLS, IRON, AND ERYTHROPOIESIS
THROMBOSIS AND HEMOSTASIS
TRANSFUSION MEDICINE
TRANSPLANTATION
VASCULAR BIOLOGY
CORRESPONDENCE
-
Cover Image
Cover Image
In inflammatory processes of the vascular wall, fibrinolysis and proteolysis may be induced via a cross-talk between monocytes or cellular microparticles bearing uPA and platelet-, fibrin-, or extracellular matrix–bound plasminogen. This mechanism of plasmin formation bypasses the requirement for co-assembly of plasminogen and uPA on the same surface. See the article by Dejouvencel et al on page 2048.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkAdvertising
- PDF Icon PDF LinkEditorial Board
Advertisement
Email alerts
Advertisement